Breast Cancer Mutation Detection via Next-Generation Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and characterizing breast cancer, such as expression profiling, face challenges in accurately identifying specific mutations and require comparison to non-neoplastic tissue, which can be cumbersome and prone to errors, especially in quantitating gene products from clinical specimens.
Innovation Solution
A method involving sequencing of DNA, RNA, or cDNA from a sample to identify specific mutations in FGFR3 and TP53 genes, like S249C and V272M, without referencing non-neoplastic tissue, using next-generation sequencing techniques and comparison to a catalog of known mutations, to determine association with breast cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If expression profiling methods are used to identify cancer mutations, then diagnostic capability is provided, but measurement precision and reliability are reduced due to difficulty in accurate quantitation of gene products from clinical specimens
Solution Approach 1:
The patent replaces the mechanical/chemical quantitation process (expression profiling requiring reverse transcription and amplification) with a sequencing-based detection system. Next-generation sequencing directly determines nucleotide sequences without requiring accurate quantitation of RNA or cDNA, thereby eliminating the quantitation complexity while maintaining or improving diagnostic accuracy for mutation identification.
2Reliability
If comparison to non-neoplastic tissue is performed to identify mutations, then specificity is improved, but ease of operation is reduced due to cumbersome sampling and processing requirements
Solution Approach 1:
The patent extracts and eliminates the requirement for non-neoplastic tissue comparison from the diagnostic workflow. By using next-generation sequencing to directly identify somatic mutations with high specificity, the method removes the need to obtain, process, and compare normal tissue samples, thereby simplifying the overall procedure while maintaining diagnostic reliability through advanced sequencing technology and bioinformatic analysis.
3Reliability
If multiple genetic markers are characterized to improve specificity, then reliability is improved, but device complexity and time requirements increase
Solution Approach 1:
The patent merges the analysis of multiple genetic markers into a single next-generation sequencing experiment. Instead of performing separate expression profiling or individual mutation assays for each marker, the sequencing platform simultaneously sequences and identifies mutations across multiple genes and markers in one integrated workflow, thereby maintaining high specificity through comprehensive marker analysis while reducing overall analysis time and procedural complexity.
Data Source
AI summary
Specific mutations of FGFR3 (S249C) and of TP53 (V272M) are identified as being characteristic of breast cancer, and of having utility in diagnosis and prognosis of an individual with breast cancer. Systems and methods useful for identification of such mutations are also presented.